In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synta Pharmaceuticals Corp.

Division of Madrigal Pharmaceuticals Inc.
www.syntapharma.com

Latest From Synta Pharmaceuticals Corp.

Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90

Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.

Platform Technologies Cancer

Madrigal Believes It Holds The Key To NASH: Clearing The Fat

Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.

StartUps and SMEs Business Strategies

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

Commercial Companies

Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys

Golden Meditech and MD Anderson establish startup focused on umbilical cord blood-derived T-regulatory therapies. Bayer and Evotec sign their second collaboration in four years, this time focused on renal disease.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Madrigal Pharmaceuticals Inc.
  • Senior Management
  • Chen Schor, Pres. & CEO
    Marc Schneebaum, SVP, CFO
  • Contact Info
  • Synta Pharmaceuticals Corp.
    Phone: (781) 274-8200
    45 Hartwell Ave.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register